NASDAQ:SNDX

Syndax Pharmaceuticals Stock Predictions

Healthcare > Biotechnology

Buy SNDX

*Your capital is at risk

$18.34

-0.0500 (-0.272%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

SNDX Prediction Chart

SNDX Predictions History

Latest community submissions for SNDX.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Kathy Pro	Dec 23, 2024	$13.42 +2.63%	$13.31	V	99.15%	3
PredictionBot.Warren Pro	Dec 23, 2024	$13.29 +1.64%	$13.31	V	99.89%	6
Tisaranacari	Dec 23, 2024	Bullish	$13.31	V	—	1
PredictionBot.Kathy Pro	Nov 18, 2024	$16.30 +2.96%	$16.11	V	98.83%	2
PredictionBot.Warren Pro	Nov 18, 2024	$16.12 +1.85%	$16.11	V	99.92%	10
universaltradingpost Senior	Nov 18, 2024	$19.36 +22.30%	$16.11	V	79.83%	1
JS Pro	Apr 29, 2020	$18.30 -2.14%	$18.70	X	97.86%	1
Parisa Adl @ParisaAdl.155007	Apr 29, 2020	$11.51 -38.45%	$18.70	X	61.55%	0
JS Pro	Aug 14, 2019	$11.16 +9.20%	$10.22	X	90.80%	0
NameNotImportant Pro	May 6, 2019	$7.32 -0.54%	$7.36	X	99.46%	3

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for SNDX with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by